Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

Part of paid clinical trials in Lexington, Kentucky.

Sponsor
Zhonglin Hao
Study ID
NCT03958045
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate survival and response rate of the combination rucaparib and nivolumab as maintenance therapy in platinum-sensitive small cell lung carcinoma.

Key Dates

Start date
Sep 4, 2019
Status verified
Oct 2024
Primary completion
Nov 15, 2022
Completion
Nov 15, 2022

Study Design

Enrollment
33 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Patients with Stage IV SCLC
    Patients with extensive stage (IV) SCLC (small cell lung cancer)

Primary Outcome Measure

Progression Free Survival [ Time Frame: 0-2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Markey Cancer Center, University of KentuckyLexingtonKentucky40536-

Find similar trials in Lexington, KY

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Markey Cancer Center, University of Kentucky· Lexington, KY

Related Studies